C4 Therapeutics, Inc. (CCCC) Operating cash flow 2019–2025
C4 Therapeutics, Inc. (CCCC) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$98.7MFY2025 · since FY2019: $55.6M → -$98.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$98.7M | -51.5% |
| FY2024 | -$65.2M | +39.0% |
| FY2023 | -$106.8M | -0.8% |
| FY2022 | -$105.9M | -21.8% |
| FY2021 | -$87.0M | -29.3% |
| FY2020 | -$67.2M | -220.9% |
| FY2019 | $55.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CCCC financial trends
CCCC RevenueCCCC Net incomeCCCC Net marginCCCC Gross profitCCCC Gross marginCCCC Operating incomeCCCC Operating marginCCCC Free cash flowCCCC Capital expendituresCCCC Return on equityCCCC Stock buybacksCCCC Dividends paidCCCC Total assetsCCCC Total liabilitiesCCCC Shareholders’ equityCCCC overview →